These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 33175110)
1. The Challenges Ahead With Monoclonal Antibodies: From Authorization to Access. Goldstein RH; Walensky RP JAMA; 2020 Dec; 324(21):2151-2152. PubMed ID: 33175110 [No Abstract] [Full Text] [Related]
2. Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process. Ison MG; Wolfe C; Boucher HW JAMA; 2020 Jun; 323(23):2365-2366. PubMed ID: 32407438 [No Abstract] [Full Text] [Related]
3. Regulatory approval for COVID-19 across the globe. Mahalmani V; Pugazhenthan T; Mittal N; Varthya SB; Medhi B Indian J Pharmacol; 2020; 52(6):457-466. PubMed ID: 33666185 [No Abstract] [Full Text] [Related]
4. Audio Interview: Covid-19 Vaccination and the Omicron Variant. Rubin EJ; Baden LR; Morrissey S N Engl J Med; 2021 Dec; 385(27):e102. PubMed ID: 34965346 [No Abstract] [Full Text] [Related]
5. 'A very, very bad look' for remdesivir. Cohen J; Kupferschmidt K Science; 2020 Nov; 370(6517):642-643. PubMed ID: 33154114 [No Abstract] [Full Text] [Related]
6. FDA Approval of Remdesivir - A Step in the Right Direction. Rubin D; Chan-Tack K; Farley J; Sherwat A N Engl J Med; 2020 Dec; 383(27):2598-2600. PubMed ID: 33264539 [No Abstract] [Full Text] [Related]
7. Commentary: "Emergency Use Authorization for Remdesivir: A Pediatric Perspective". Noel GJ; Connor E Pediatr Infect Dis J; 2020 Sep; 39(9):e234. PubMed ID: 32639464 [No Abstract] [Full Text] [Related]
10. What Do We Know About Remdesivir Drug Interactions? Yang K Clin Transl Sci; 2020 Sep; 13(5):842-844. PubMed ID: 32402130 [No Abstract] [Full Text] [Related]
11. Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19. Chua KP; Conti RM JAMA Intern Med; 2020 Oct; 180(10):1273-1274. PubMed ID: 32804187 [No Abstract] [Full Text] [Related]
12. A Proposed Lottery System to Allocate Scarce COVID-19 Medications: Promoting Fairness and Generating Knowledge. White DB; Angus DC JAMA; 2020 Jul; 324(4):329-330. PubMed ID: 32579158 [No Abstract] [Full Text] [Related]
13. Audio Interview: What the U.S. Response to Covid-19 Looks Like Today. Rubin EJ; Baden LR; Morrissey S N Engl J Med; 2020 Nov; 383(19):e123. PubMed ID: 33211936 [No Abstract] [Full Text] [Related]
14. Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir. Ueda M; Tanimoto T; Murayama A; Ozaki A; Kami M Clin Pharmacol Ther; 2022 Mar; 111(3):545-547. PubMed ID: 33882157 [No Abstract] [Full Text] [Related]
15. Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment. Chatterjee S Drug Res (Stuttg); 2021 Mar; 71(3):138-148. PubMed ID: 33124007 [TBL] [Abstract][Full Text] [Related]
16. Remdesivir emergency approvals: a comparison of the U.S., Japanese, and EU systems. Saint-Raymond A; Sato J; Kishioka Y; Teixeira T; Hasslboeck C; Kweder SL Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1095-1101. PubMed ID: 32909843 [TBL] [Abstract][Full Text] [Related]
17. Audio Interview: Covid-19 and the President. Rubin EJ; Baden LR; Morrissey S N Engl J Med; 2020 Oct; 383(15):e104. PubMed ID: 33027580 [No Abstract] [Full Text] [Related]
20. Treatments for COVID-19: where are we now? Mendes A Br J Community Nurs; 2020 Aug; 25(8):412-413. PubMed ID: 32757900 [No Abstract] [Full Text] [Related] [Next] [New Search]